| 12390464 |
Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors |
Michael N. Greco, Michael Alan Green, Don Zhang, Jirong Peng |
2025-08-19 |
|
| 12258365 |
Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof |
Don Zhang, Jirong Peng, Michael N. Greco, Michael Alan Green |
2025-03-25 |
|
| 12187707 |
Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof |
Michael N. Greco, Michael Alan Green, Jirong Peng, Victoria Lynn Wilde, Don Zhang |
2025-01-07 |
|
| 11414401 |
Substituted 2-anilinopyrimidine derivatives as EGFR modulators |
Jirong Peng, Michael N. Greco, Michael Alan Green, Victoria Lynn Wilde, Don Zhang |
2022-08-16 |
|
| 11352341 |
2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof |
Michael N. Greco, Jirong Peng, Don Zhang |
2022-06-07 |
|
| 11180478 |
Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
Michael N. Greco, Michael Alan Green, Jirong Peng, Victoria Lynn Wilde, Don Zhang |
2021-11-23 |
|
| 11052086 |
2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers |
Michael N. Greco, Michael Alan Green, Jirong Peng, Victoria Lynn Wilde, Don Zhang |
2021-07-06 |
|
| 10844045 |
Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof |
Michael N. Greco, Michael Alan Green, Jirong Peng, Victoria Lynn Wilde, Don Zhang |
2020-11-24 |
|
| 10590111 |
Substituted 2-anilinopyrimidine derivatives as EGFR modulators |
Jirong Peng, Michael N. Greco, Michael Alan Green, Victoria Lynn Wilde, Don Zhang |
2020-03-17 |
|
| 10239864 |
2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof |
Michael N. Greco, Jirong Peng, Victoria Lynn Wilde, Don Zhang |
2019-03-26 |
|
| 9878994 |
2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof |
Michael N. Greco, Jirong Peng, Victoria Lynn Wilde, Don Zhang |
2018-01-30 |
|
| 8536189 |
Spiropiperidines for use as tryptase inhibitors |
Stephen C. Yabut, Brett A. Tounge, Bruce E. Maryanoff, Han-Cheng Zhang |
2013-09-17 |
$51,022,000 |
| 8158792 |
Spiropiperidines for use as tryptase inhibitors |
Stephen C. Yabut, Brett A. Tounge, Bruce E. Maryanoff, Han-Cheng Zhang |
2012-04-17 |
$41,469,000 |
| 7825110 |
Substituted spiroheterocycles |
Min Xiang, Mona Patel, Philip Rybczynski, Joseph Gunnet, Keith Demarest +3 more |
2010-11-02 |
$70,286,000 |
| 7825111 |
Substituted spiroheterocycles |
Min Xiang, Mona Patel, Philip Rybczynski, Joseph Gunnet, Keith Demarest +3 more |
2010-11-02 |
$70,286,000 |
| 7718673 |
Isonipecotamides for the treatment of integrin-mediated disorders |
William J. Hoekstra, Bruce E. Maryanoff |
2010-05-18 |
|
| 7132418 |
Peptidyl heterocyclic ketones useful as tryptase inhibitors |
Bruce E. Maryanoef, Stephen C. Yabut |
2006-11-07 |
$4,252,000 |
| 7081460 |
Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
William J. Hoekstra, Edward C. Lawson |
2006-07-25 |
$10,380,000 |
| 6495523 |
Tricyclic monosaccharide derivatives useful in treating acute ischemia-induced neurodegeneration |
Bruce E. Maryanoff, Richard P. Shank |
2002-12-17 |
|
| 6469036 |
Peptidyl heterocyclic ketones useful as tryptase inhibitors |
Bruce E. Maryanoff, Stephen C. Yabut |
2002-10-22 |
|
| 6323219 |
Methods for treating immunomediated inflammatory disorders |
— |
2001-11-27 |
|
| 6069254 |
Carboxamide derivatives of piperidine for the treatment of thrombosis disorders |
William J. Hoekstra, Bruce E. Maryanoff |
2000-05-30 |
$184,414,000 |
| 5827860 |
Peptidyl heterocycles useful in the treatment of thrombin related disorders |
Bruce E. Maryanoff |
1998-10-27 |
$68,827,000 |
| 5827866 |
Peptidyl heterocycles useful in the treatment of thrombin related disorders |
Bruce E. Maryanoff |
1998-10-27 |
$68,827,000 |
| 5523308 |
Peptidyl heterocycles useful in the treatment of thrombin related disorders |
Bruce E. Maryanoff |
1996-06-04 |
|
